Short Bowel Syndrome With a Conjugated Bilirubin of 2.1: What Is the Best Next Step?
Carousel1 min read·Published Nov 2026

Short Bowel Syndrome With a Conjugated Bilirubin of 2.1: What Is the Best Next Step?

Clinical case question about managing elevated bilirubin in infant with short bowel syndrome on parenteral nutrition.
Answer slide showing option C: continue and observe, with guidance on cholestasis management in intestinal rehab.
Slide explaining two clinical bilirubin thresholds for cholestasis and liver disease in infants.
Slide 5 of 7 on modifiable risk factors for intestinal failure-associated liver disease and management strategies.
Blue slide explaining lipid management strategy in intestinal rehabilitation for pediatric patients.
Final slide encouraging viewers to follow for more pediatric surgery education content.
1 / 7

Carousel · Nov 2026 · 1 min read

In brief

In brief

Educational content on intestinal rehabilitation strategies, likely covering management approaches for short bowel syndrome and intestinal failure in pediatric patients.

Written by the GCMD Library team from the carousel.

Slides

7 pages · click to turn to one
Intestinal rehabilitation — short bowel syndrome. A social-media carousel made possible by Cincinnati Children's.
The text on each slide
  1. Intestinal Rehab | Expert | Made possible by Cincinnati Children's | An infant with short bowel syndrome on parenteral nutrition has a conjugated bilirubin of 2.1 mg/dL for the past two weeks. Growth is on track. They are on a standard lipid emulsion at conventional dosing. | WHAT IS THE BEST NEXT STEP? | A.) Dose-restrict the lipid to 1 g/kg/day | B.) Start Omegaven | C.) Continue current management and observe | 1/7
  2. Intestinal Rehab | Expert | Made possible by Cincinnati Children's | THE ANSWER | c.) CONTINUE AND OBSERVE | Observe and address modifiable risk factors. A conjugated bilirubin of 2 mg/dL meets the definition of cholestasis. | 2/7
  3. Intestinal Rehab | Expert | Made possible by Cincinnati Children's | THE ANSWER | D.) CONTINUE AND OBSERVE | Observe and address modifiable risk factors. A conjugated bilirubin of 2 mg/dL meets the definition of cholestasis. | 2/7
  4. Intestinal Rehab | Expert | THE 2 BILIRUBIN THRESHOLDS | A bilirubin level ≥ 2 mg/dL for two weeks defines cholestasis. | A level of 5 to 6 mg/dL indicates advanced liver disease. | Most infants with levels around 2 mg/dL improve with observation alone. | 4/7 | Made possible by Cincinnati Children's
  5. Intestinal Rehab | Expert | ADDRESS THE MODIFIABLE RISK FACTORS | Risk factors for intestinal failure-associated liver disease include prematurity, lack of enteral feeding, sepsis, and the composition of parenteral nutrition (PN) itself. | Prioritize enteral feeding, optimize surgical anatomy to support feeding, protect the central line, and manage PN composition. A rising bilirubin earns a search for the cause. | 5/7 | Made possible by Cincinnati Children's
  6. Intestinal Rehab | Expert | Made possible by Cincinnati Children's | THE TAKEAWAY | For this patient, there is no need to change the lipid emulsion. Reducing the lipid dose limits calories for a potential benefit on cholestasis. | At this bilirubin level, the work is optimizing nutrition. | Essential fatty acid deficiency is rare, and a further reason to leave the dose alone. | 6/7
  7. Intestinal Rehab | Expert | Made possible by Cincinnati Children's | FOLLOW FOR MORE PEDIATRIC SURGERY EDUCATION. | 7/7
Intelligent Search· scoped to this carousel · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.